Skip to main content
Premium Trial:

Request an Annual Quote

TM Bioscience Issues Warrants for $14.4M

Premium

TORONTO--TM Biosciences announced that is has agreed, subject to regulatory approval, to issue up to 18 million special warrants on a private placement basis at 80 cents per special warrant, for aggregate gross proceeds of $14.4 million. The issue and sale of more than 12 million of the special warrants for proceeds of $10.1 million will be by way of a private placement underwritten by Yorkton Securities. The remaining warrants will be purchased by Canadian Medical Discoveries Fund for proceeds of $4.3 million. TM designs, develops, and commercializes DNA products for medical diagnostics, therapeutics, biochips, functional genomics, and bioinformatics.

Filed under

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.